Cyprus ppe import & distribution company

CCL was incorporated in Cyprus on 10 June 2020 as a private limited liability company in accordance with the Cyprus Companies Law, Cap. 113 with registered number HE410016.

CCL supplies disposable / personal protection equipment (PPE) products, with customer focus exceeding expectations.

CCL is now well-positioned to cater for all industries and sectors - not just the medical ones.

A-list customers, second to none, varying between SMEs and large organisations, across a wide range of industries and sectors.

Audited Financial Statements are available for the year ended 2023. Trial Balance, Profit and Loss Account and Stock Count are available as of TO DATE.

CCL’s suppliers include global medical enterprises and listed high-tech manufacturing companies. CCL deals directly with the factories without any 3rd party agents i.e. no middle-men.

CCL has obtained from the competent authority the requisite license (no. B2159) for antiseptic gel which required a period of approximately 1 year to do so via the applicable application procedure and pursuant to the applicable legislation.

Following the acquisition of CCL, Management is prepared to stay on board, if necessary, albeit for a limited timeframe, to assist with a smooth transition of CCL to its new owner.

CUSTOMER BASE

healthcare institutions

pharmaceutical companies

medical laboratories

five star hotels

financial institutions

catering companies

multipurpose centres

groups of restaurants

food and beverage processing groups

winery estates

car distributors

ship owning companies

CCL is entering its fourth year of operation and continues to expand in turnover and customer base. Its customer base continues increasing in both number of customers and the amount that they order.

If the profit grows more the shareholders’ asking valuation of CCL will be proportionally more and indeed, they may keep CCL for a few more years.

At the current moment there may be opportunities for someone to buy 100% of CCL outright only.

The shareholders expect completion of closing its acquisition before the end of 2024.